Adjuvant nab-paclitaxel plus S-1 versus oxaliplatin plus capecitabine after curative D2 gastrectomy in patients with stage III gastric adenocarcinoma: a phase 3 open-label, randomized controlled trial

被引：0
|
作者：
Yu Pengfei
Du, Yian
Xu, Zhiyuan
Yang, Litao
Ying, Jieer
Chen, Ping
Wei, Yunhai
Wu, Yingjie
Yan, Zhilong
Xu, Hongtao
Zhang, Xiaojing
Li, Yong
Zheng, Zhichao
Chen, Zhiheng
Cheng, Xiangdong
机构：
[1] Univ Chinese Acad Sci, Canc Hosp, Zhejiang Canc Hosp, Hangzhou, Peoples R China
[2] Ningbo Second Hosp, Ningbo, Peoples R China
[3] Zhejiang Univ, Huzhou Hosp, Huzhou Cent Hosp, Huzhou, Peoples R China
[4] Ningbo Univ, Affiliated Peoples Hosp, Ningbo, Peoples R China
[5] Ningbo First Hosp, Ningbo, Peoples R China
[6] Lishui Cent Hosp, Lishui, Peoples R China
[7] Huzhou Teachers Coll, Affiliated Hosp, 1 Peoples Hosp Huzhou, Huzhou, Peoples R China
[8] Nanchang Univ, Affiliated Hosp 1, Nanchang, Jiangxi, Peoples R China
[9] Liaoning Canc Hosp & Inst, Shenyang, Peoples R China
[10] First Hosp Jiaxing, Jiaxing, Peoples R China
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2023年 / 41卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
386
引用
收藏
页码：386 / 386
页数：1
相关论文
共 50 条
  • [1] Adjuvant nab-paclitaxel plus S-1 versus capecitabine plus oxaliplatin for patients with stage III gastric adenocarcinoma after D2 dissection: A multicenter, open-label, randomized phase 3 study
    Yu, Pengfei
    Du, Yian
    Xu, Zhiyuan
    Yang, Litao
    Ying, Jieer
    Chen, Ping
    Wei, Yunhai
    Wu, Yingjie
    Zhang, Xiaojing
    Yan, Zhilong
    Chen, Zhiheng
    Xu, Hongtao
    Li, Yong
    Zheng, Zhichao
    Xu, Nong
    Cheng, Xiangdong
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [2] A randomized, controlled, multi-center, open-label study of adjuvant nab-paclitaxel plus S-1 (AS) versus capecitabine plus oxaliplatin (CapeOX) for stage III gastric cancer after D2 resection.
    Yu, Pengfei
    Du, Yian
    Xu, Zhiyuan
    Yang, Litao
    Ying, Jieer
    Wang, Yongxiang
    Chen, Ping
    Wei, Yunhai
    Xu, Hongtao
    Xu, Nong
    Cheng, Xiangdong
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [3] Adjuvant albumin-bound paclitaxel combined with S-1 vs. oxaliplatin combined with capecitabine after D2 gastrectomy in patients with stage III gastric adenocarcinoma: a phase III multicenter, open-label, randomized controlled clinical trial protocol
    Xiangdong Cheng
    Dan Wu
    Nong Xu
    Luchuan Chen
    Zhilong Yan
    Ping Chen
    Lei Zhou
    Jianfa Yu
    Jiuwei Cui
    Wei Li
    Chang Wang
    Wenming Feng
    Yunhai Wei
    Pengfei Yu
    Yian Du
    Jieer Ying
    Zhiyuan Xu
    Litao Yang
    Yunli Zhang
    BMC Cancer, 21
  • [4] Adjuvant albumin-bound paclitaxel combined with S-1 vs. oxaliplatin combined with capecitabine after D2 gastrectomy in patients with stage III gastric adenocarcinoma: a phase III multicenter, open-label, randomized controlled clinical trial protocol
    Cheng, Xiangdong
    Wu, Dan
    Xu, Nong
    Chen, Luchuan
    Yan, Zhilong
    Chen, Ping
    Zhou, Lei
    Yu, Jianfa
    Cui, Jiuwei
    Li, Wei
    Wang, Chang
    Feng, Wenming
    Wei, Yunhai
    Yu, Pengfei
    Du, Yian
    Ying, Jieer
    Xu, Zhiyuan
    Yang, Litao
    Zhang, Yunli
    BMC CANCER, 2021, 21 (01)
  • [5] Adjuvant capecitabine and oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): a phase 3 open-label, randomised controlled trial
    Bang, Yung-Jue
    Kim, Young-Woo
    Yang, Han-Kwang
    Chung, Hyun Cheol
    Park, Young-Kyu
    Lee, Kyung Hee
    Lee, Keun-Wook
    Kim, Yong Ho
    Noh, Sang-Ik
    Cho, Jae Yong
    Mok, Young Jae
    Kim, Yeul Hong
    Ji, Jiafu
    Yeh, Ta-Sen
    Button, Peter
    Sirzen, Florin
    Noh, Sung Hoon
    LANCET, 2012, 379 (9813): : 315 - 321
  • [6] Clinicians preference of adjuvant S-1 versus capecitabine plus oxaliplatin after curative gastrectomy
    Hwang, In Gyu
    Park, Se Hoon
    Kang, Jung Hun
    Kim, Young Saing
    Oh, Sung Yong
    Won, Young-Woong
    Lee, Soonil
    Ji, Jun Ho
    Chi, Kyong-Choun
    Lee, Ha Yeon
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [7] Perioperative versus adjuvant S-1 plus oxaliplatin chemotherapy for stage II/III resectable gastric cancer (RESONANCE): a randomized, open-label, phase 3 trial
    Wang, Xinxin
    Lu, Canrong
    Wei, Bo
    Li, Shuo
    Li, Ziyu
    Xue, Yingwei
    Ye, Yingjiang
    Zhang, Zhongtao
    Sun, Yihong
    Liang, Han
    Li, Kai
    Zhu, Linghua
    Zheng, Zhichao
    Zhou, Yanbing
    He, Yulong
    Li, Fei
    Wang, Xin
    Liang, Pin
    Huang, Hua
    Li, Guoli
    Shen, Xian
    Ji, Jiafu
    Tang, Yun
    Xu, Zekuan
    Chen, Lin
    JOURNAL OF HEMATOLOGY & ONCOLOGY, 2024, 17 (01) : 17
  • [8] Perioperative versus adjuvant S-1 plus oxaliplatin chemotherapy for stage II/III resectable gastric cancer (RESONANCE): a randomized, open-label, phase 3 trial
    Xinxin Wang
    Canrong Lu
    Bo Wei
    Shuo Li
    Ziyu Li
    Yingwei Xue
    Yingjiang Ye
    Zhongtao Zhang
    Yihong Sun
    Han Liang
    Kai Li
    Linghua Zhu
    Zhichao Zheng
    Yanbing Zhou
    Yulong He
    Fei Li
    Xin Wang
    Pin Liang
    Hua Huang
    Guoli Li
    Xian Shen
    Jiafu Ji
    Yun Tang
    Zekuan Xu
    Lin Chen
    Journal of Hematology & Oncology, 17
  • [9] Phase II study of adjuvant chemotherapy of S-1 plus oxaliplatin for patients with stage III gastric cancer after D2 gastrectomy
    Shitara, Kohei
    Chin, Keisho
    Yoshikawa, Takaki
    Katai, Hitoshi
    Terashima, Masanori
    Ito, Seiji
    Hirao, Motohiro
    Yoshida, Kazuhiro
    Oki, Eiji
    Sasako, Mitsuru
    Emi, Yasunori
    Tsujinaka, Toshimasa
    GASTRIC CANCER, 2017, 20 (01) : 175 - 181
  • [10] Phase II study of adjuvant chemotherapy of S-1 plus oxaliplatin for patients with stage III gastric cancer after D2 gastrectomy
    Kohei Shitara
    Keisho Chin
    Takaki Yoshikawa
    Hitoshi Katai
    Masanori Terashima
    Seiji Ito
    Motohiro Hirao
    Kazuhiro Yoshida
    Eiji Oki
    Mitsuru Sasako
    Yasunori Emi
    Toshimasa Tsujinaka
    Gastric Cancer, 2017, 20 : 175 - 181
12345